National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

COX-2 inhibitor TG01
An orally bioavailable anti-inflammatory agent with potential antiangiogenic and antineoplastic activities. COX-2 inhibitor TG01 binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. TG01-mediated inhibition of COX-2 may induce tumor cell apoptosis and inhibit tumor cell proliferation and tumor angiogenesis. COX-related metabolic pathways may represent crucial regulators of cellular proliferation and angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code names:TG01
TP2001



Previous:Cortril, Corynebacterium granulosum P40, Cosmegen, Cotrim, Coumadin
Next:coxsackievirus A21, CP-4055, CP-724,714, CpG oligodeoxynucleotide, creatine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov